Sanofi, Lilly & Novo accused of pricing collusion
November 4, 2016Manufacturing and Production, Medical Communications, Sales and Marketing
Bernie Sanders has continued his assault on pharma pricing after calling out Eli Lilly earlier this week by implicating Lilly, …
Lonza grows manufacturing capability by opening further site
November 4, 2016Medical Communications Lonza, drug product services, manufacturing
Lonza, a Swiss multinational chemical and biotechnology company, has opened a new manufacturing facility in Basel, where their headquarters is …
AstraZeneca’s post-heart attack drug gets NICE recommendation
November 4, 2016Medical Communications, Sales and Marketing AstraZeneca, Brillique, NICE, heart attack
AstraZeneca’s Brillique (ticagrelor) has received final recommendation from the National Institute of Health and Care Excellence (NICE) as a prevention …
Blood cancer sufferers to receive early access to BMS’ Opdivo
November 3, 2016Medical Communications Bristol-Myers Squibb, lyphoma, opdivo
Bristol-Myers Squibb has announced that their immunotherapy drug, Opdivo (nivolumab), will be made available to patients in the UK through …
Clinical trials and their patients: The rising costs and how to stem the loss
November 3, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing clinical trials
The pharmaceutical industry has a big problem and it’s one that keeps getting worse every year – how to stop …
NICE approves first new drug for breast cancer in a decade
November 3, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing
NICE has approved Eisai’s Halaven (eribulin) for routine treatment of sufferers of locally advanced or metastatic breast cancer that has …
Lily increases diabetes drug by 700% over 20 years
November 3, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Bernie Sanders, Eli Lily, Humalog, diabetes
It has come to light that, over a 20 year period, Eli Lily has increased the price of its diabetes …
MSD’s Alzheimer’s study could break new ground for treatment
November 3, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Alzheimer's, MSD, clinical trials
MSD, known as Merck in North America, has published results of a Phase I trial of verubecestat. The drug is …
FDA issues warning letter after Chinese firm impedes investigation
November 2, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing China, FDA
The US Food and Drugs Administration (FDA) has issued a Chinese firm with a warning letter after claims it intentionally …
Gilead quietly drops drugs from line up alongide Q3 results
November 2, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Abzena, Gilead, research and development
Gilead Sciences followed Pfizer in discreetly dropping a drug alongside its third quarter profit reports. The drug in question, for …
Multi Packaging Solutions wins ‘Packaging Company of the Year’
November 2, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing
Multi Packaging Solutions (“MPS”)(NYSE: MPSX), a global market leader in healthcare, spirits, confectionery and media packaging, has been voted the …
Avacta joins major US cancer centre for CAR-T immunotherapy development
November 2, 2016Research and Development Avacta, Memorial Sloan Kettering Cancer Center
Biotherapeutic and research reagent developer Avacta has announced it will collaborate with New York’s Memorial Sloan Kettering Cancer Center (MSK, …
Nimbus Therapeutics receives $200 million payment from Gilead
November 2, 2016Research and Development Gilead Sciences, Nimbus Therapeutics, nash
Nimbus Therapeutics only signed a deal with Gilead Sciences back in April of this year and yet have already received …
Celgene partners with IBM for new pharmacovigilance platform
November 2, 2016Research and Development, Sales and Marketing Celgene, Watson, ibm
IBM is set to join forces with Celgene to develop a new drug safety evaluation platform, it has emerged. Running …
Valeant looking at selling core asset to manage debt
November 2, 2016Research and Development Takeda Pharmaceutical, Valeant pharmaceutical, salix
Valeant is rumoured to be looking into selling its Salix drugs business to Takeda Pharmaceutical, with figures floated of a …
Pfizer surprises industry by ending development of projected blockbuster
November 1, 2016Research and Development Pfizer, cholesterol, clinical trials
Pfizer announced the news that it would no longer be developing an experimental cholesterol lowering drug. The drug had been …
FDA approves clinical trial of Cuban lung cancer vaccine
November 1, 2016Manufacturing and Production, Sales and Marketing Cuba, US, Vaccine, cimavax, clinical trials
The thawing of relations between the US and Cuba has allowed a pioneering treatment for non-small cell lung cancer to …
EMA has validated Merck and Pfizer’s MAA for avelumab
November 1, 2016Manufacturing and Production, Sales and Marketing EMA, Merck KGaA, Pfizer, avelumab
The European Medicines Agency has validated the Marketing Authorisation Application for avelumab for the proposed indication of metastatic Merkel cell …
Woodley Equipment Company Exhibiting at Partnerships in Clinical Trials Europe 2016
November 1, 2016PCT, clinical trials
Woodley Equipment Company is exhibiting at Partnerships in Clinical Trials Europe
Promising new study for children’s brain cancer
November 1, 2016Manufacturing and Production brain cancer, children, oncology
There has been positive news coming from researchers at the Huntsman Cancer Institute, at the University of Utah, reporting on …
Latest content
Global coalition calls for stronger government action on COPD
Global health researchers call for more equitable partnerships
Liverpool launches £20m lab for infectious disease drug discovery
Circle Health Group expands into UK laboratory operations
